首页 | 本学科首页   官方微博 | 高级检索  
     


Novel,human cell line‐derived recombinant factor VIII (human‐cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety
Authors:T. Lissitchkov  K. Hampton  M. von Depka  C. Hay  S. Rangarajan  E. Tuddenham  K. Holstein  A. Huth‐Kühne  I. Pabinger  S. Knaub  J. Bichler  J. Oldenburg
Affiliation:1. Specialised Hospital for Active Treatment “Joan Pavel”, Sofia, Bulgaria;2. Royal Hallamshire Hospital, Sheffield, UK;3. Werlhof‐Institut für H?mostaseologie GmbH, Hannover, Germany;4. Manchester Royal Infirmary, Manchester, UK;5. Basingstoke and North Hampshire Hospital, Basingstoke, UK;6. Royal Free Hospital, London, UK;7. University Hospital Hamburg‐Eppendorf, Hamburg, Germany;8. SRH Kurpfalzkrankenhaus and Hemophilia Center, Heidelberg, Germany;9. Medical University of Vienna, Vienna, Austria;10. Octapharma AG, Lachen, Switzerland;11. Institute of Experimental Haematology and Transfusion Medicine, Bonn, Germany
Abstract:
Keywords:factor VIII inhibitors  haemophilia A  human cell line factor VIII  Nuwiq  prophylaxis  recombinant factor VIII
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号